Here's what investors need to know about this successful yet underappreciated cancer drug developer.
News & Analysis: Blueprint Medicines
Roche is licensing commercial rights to Blueprint Medicines RET-inhibitor pralsetinib.
Blueprint Medicines and Deciphera Pharmaceuticals were going toe-to-toe developing treatments for this rare cancer. Investors can now call the winner.
BPMC earnings call for the period ending March 31, 2020.
A closely watched drug candidate didn't meet the primary endpoint of a late-stage trial, which creates a wide-open opportunity for a competitor.
Disruptions in clinical trials and delayed regulatory decisions could slow the rate of new drug approvals.
BPMC earnings call for the period ending December 31, 2019.
Meet EQRx, a biotech startup founded by an industry legend who wants to develop new therapies sold at generic prices, undermining the drug industry's profits.
They have what deep-pocketed pharmaceutical giants want.
Here's why you might want to buy Amarin and Blueprint Medicines as soon as possible.